FDA Approves Ibrutinib for Patients with Marginal Zone Lymphoma

January 27, 2017

The U.S. Food and Drug Administration (FDA) approved ibrutinib for the treatment of patients with marginal zone lymphoma (a type of B-cell lymphoma) who had already received at least one treatment. FDA granted accelerated approval so clinical trials are still ongoing to confirm findings. Read more here.

To learn more about treatment for non-Hodgkin lymphoma, visit My PearlPoint